Longeveron (NASDAQ:LGVN) Given Buy Rating at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Longeveron (NASDAQ:LGVN) in a report released on Monday morning,Benzinga reports. The brokerage currently has a $10.00 price target on the stock.

Separately, Maxim Group dropped their price target on shares of Longeveron from $15.00 to $6.00 and set a “buy” rating on the stock in a research report on Tuesday, August 27th.

Longeveron Price Performance

LGVN stock opened at $1.96 on Monday. The stock has a market capitalization of $29.09 million, a PE ratio of -0.31 and a beta of 0.36. The company’s 50-day moving average is $2.02 and its 200-day moving average is $2.13. Longeveron has a 1 year low of $0.77 and a 1 year high of $23.90.

Longeveron (NASDAQ:LGVN) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.34) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.53) by $0.19. Longeveron had a negative net margin of 967.49% and a negative return on equity of 142.43%. The company had revenue of $0.77 million for the quarter, compared to analysts’ expectations of $0.34 million. During the same quarter in the prior year, the firm earned ($2.80) EPS. On average, analysts anticipate that Longeveron will post -3.72 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Longeveron

Large investors have recently added to or reduced their stakes in the business. State Street Corp bought a new position in Longeveron in the 3rd quarter valued at about $29,000. Geode Capital Management LLC lifted its position in shares of Longeveron by 316.0% during the 3rd quarter. Geode Capital Management LLC now owns 128,947 shares of the company’s stock worth $250,000 after buying an additional 97,953 shares in the last quarter. Finally, Renaissance Technologies LLC bought a new position in shares of Longeveron during the 2nd quarter worth approximately $236,000. Institutional investors own 10.01% of the company’s stock.

About Longeveron

Longeveron Inc, a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company’s lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors.